Metformin × glycemic control

TrialJAMA network open2026

HRS-7535 for Type 2 Diabetes Inadequately Controlled With Metformin: A Randomized Clinical Trial.

Lixin Guo et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedrandomised · 2026

Randomised comparison

Probably lowered glycemic control

−1.19percentage points−1.54 to −0.84

As reported

difference −1.19 %, 95% CI −1.54 to −0.84

Randomised comparison

Probably lowered glycemic control

−0.94percentage points−1.43 to −0.45

As reported

difference −0.94 %, 95% CI −1.43 to −0.45

Two numbers in the abstract

the abstract, start to end

changes in HbA1c level at week 16 were -1.19% (95% CI, -1.54% to -0.84%) with the 15-mg dose, -1.59% (95% CI, -1.94% to -1.24%) with the 30-mg dose, -1.82% (95% CI, -2.16% to -1.48%) with the 60-mg dose, and -1.64% (95% CI, -1.97% to -1.30%) with the 90-mg dose compared with -0.25% (95% CI, -0.60% to 0.09%) with placebo; placebo-adjusted differences ranged from -0.94% (95% CI, -1.43% to -0.45%) to

← favours treatmentfavours comparator →
could be chance
Glycemic control
−1.19−1.54 to −0.84
Glycemic control
−0.94−1.43 to −0.45
MetforminGlycemic control

Metformin × glycemic controlhelps?replicated

unlikelylikely
0.840.84 without it
← favours treatmentfavours comparator →
this papermore certainless certain
1 / 5

1 paper cites it

2026
this papercites it

The trial

Full record →Abstract, authors, funding and every citing paper · PMID 42234428